INSP Stock Analysis: Inspire Medical Systems | NYSE
Medical Devices | NYSE, USA | Market Cap: 1.823m USD | 12M Return: -26.9% | US4577301090 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.1M
Qual. Beats: 16
Rev. Trend: 95.6%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 8.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company that develops and commercializes minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and select international markets. Its flagship offering, the Inspire system, is an implantable neurostimulation device that continuously monitors a patients breathing and delivers mild stimulation to the hypoglossal nerve to keep the airway open during sleep, serving patients with moderate to severe OSA. The company was incorporated in 2007, is headquartered in Golden Valley, Minnesota, and operates within the medical device industry as a direct-to-physician and direct-to-patient business model targeting an underserved OSA population that struggles with traditional first-line therapies such as continuous positive airway pressure (CPAP).
- GLP-1 weight loss drugs could shrink OSA patient pool
- U.S. Inspire procedure volume drives revenue growth
- Medicare and private insurer reimbursement coverage expands
| Net Income: 135.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.05 > 1.0 |
| NWC/Revenue: 59.80% < 20% (prev 55.71%; Δ 4.10% < -1%) |
| CFO/TA 0.17 > 3% & CFO 157.1m > Net Income 135.0m |
| Net Debt (-291.6m) to EBITDA (83.1m): -3.51 < 3 |
| Current Ratio: 8.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.9m) vs 12m ago -1.92% < -2% |
| Gross Margin: 86.13% > 18% (prev 84.47%; Δ 1.66% > 0.5%) |
| Asset Turnover: 104.0% > 50% (prev 107.4%; Δ -3.36% > 0%) |
| Interest Coverage Ratio: 480.9 > 6 (EBIT TTM 65.9m / Interest Expense TTM 137k) |
| A: 0.58 (Total Current Assets 608.7m - Total Current Liabilities 71.2m) / Total Assets 926.0m |
| B: -0.17 (Retained Earnings -157.5m / Total Assets 926.0m) |
| C: 0.08 (EBIT TTM 65.9m / Avg Total Assets 864.1m) |
| D: 8.22 (Book Value of Equity 825.6m / Total Liabilities 100.4m) |
| Altman-Z'' = 12.40 = AAA |
| DSRI: 0.72 (Receivables 103.3m/137.7m, Revenue 898.7m/861.3m) |
| GMI: 0.98 (GM 84.47% / 86.13%) |
| AQI: 1.38 (AQ_t 0.21 / AQ_t-1 0.15) |
| SGI: 1.04 (Revenue 898.7m / 861.3m) |
| TATA: -0.02 (NI 135.0m - CFO 157.1m) / TA 926.0m) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of September 05, 2026, the stock is trading at USD 63.08 with a total of 425,705 shares traded. Over the past week, the price has changed by +2.67%, over one month by -1.65%, over three months by +49.51% and over the past year by -26.92%.
Current recommended Stop Loss: 60.10 (which is 4.7% or 1.2 ATR below the current price).
Inspire Medical Systems has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy INSP.
- StrongBuy: 8
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 60.4 | -4.2% |
P/E Trailing = 13.9227
P/E Forward = 52.9101
P/S = 2.0288
P/B = 2.1543
Revenue TTM = 898.7m USD
EBIT TTM = 65.9m USD
EBITDA TTM = 83.1m USD
Long Term Debt = unknown (none)
Short Term Debt = 2.16m USD (from shortTermDebt, last fiscal year)
Debt = 29.1m USD (from shortLongTermDebtTotal, last quarter) (leases 29.1m already included)
Net Debt = -291.6m USD (calculated: Debt 29.1m - CCE 320.7m)
Enterprise Value = 1.53b USD (1.82b + Debt 29.1m - CCE 320.7m)
Interest Coverage Ratio = 480.9 (Ebit TTM 65.9m / Interest Expense TTM 137k)
EV/FCF = 13.08x (Enterprise Value 1.53b / FCF TTM 117.1m)
FCF Yield = 7.64% (FCF TTM 117.1m / Enterprise Value 1.53b)
FCF Margin = 13.03% (FCF TTM 117.1m / Revenue TTM 898.7m)
Net Margin = 15.03% (Net Income TTM 135.0m / Revenue TTM 898.7m)
Gross Margin = 86.13% ((Revenue TTM 898.7m - Cost of Revenue TTM 124.6m) / Revenue TTM)
Gross Margin QoQ = 85.48% (prev 86.47%)
Tobins Q-Ratio = 1.65 (Enterprise Value 1.53b / Total Assets 926.0m)
Interest Expense / Debt = 0.47% (Interest Expense 137k / Debt 29.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 52.0m (EBIT 65.9m * (1 - 21.00%))
Current Ratio = 8.55 (Total Current Assets 608.7m / Total Current Liabilities 71.2m)
Debt / Equity = 0.04 (Debt 29.1m / totalStockholderEquity, last quarter 825.6m)
Debt / EBITDA = -3.51 (Net Debt -291.6m / EBITDA 83.1m)
Debt / FCF = -2.49 (Net Debt -291.6m / FCF TTM 117.1m)
Total Stockholder Equity = 766.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.63% (Net Income 135.0m / Total Assets 926.0m)
RoE = 17.62% (Net Income TTM 135.0m / Total Stockholder Equity 766.4m)
RoCE = 7.71% (EBIT 65.9m / Capital Employed (Total Assets 926.0m - Current Liab 71.2m))
RoIC = 6.41% (NOPAT 52.0m / Invested Capital 812.0m)
WACC = 9.16% (E(1.82b)/V(1.85b) * Re(9.30%) + D(29.1m)/V(1.85b) * Rd(0.47%) * (1-Tc(0.21)))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -74.81 | Cagr: -1.02%
[DCF] Terminal Value 75.39% ; FCFF base≈104.3m ; Y1≈119.5m ; Y5≈175.9m
[DCF] Fair Price = 90.22 (EV 2.32b - Net Debt -291.6m = Equity 2.61b / Shares 28.9m; r=9.16% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.63 | # QB: 16
Revenue Correlation: 95.59 | Revenue CAGR: 18.69% | SUE: 3.23 | # QB: 4
EPS current Quarter (2026-09-30): EPS=0.09 | Chg30d=-42.31% | Revisions=-46% | Analysts=13
EPS current Year (2026-12-31): EPS=1.25 | Chg30d=+38.72% | Revisions=+80% | GrowthEPS=-48.5% | GrowthRev=-6.4%
EPS next Year (2027-12-31): EPS=1.54 | Chg30d=+19.95% | Revisions=+67% | GrowthEPS=+23.3% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +43% (up=25, down=9)